Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-line Treatment of CLL/SLL
NCT03462719Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of ibrutinib and venetoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-Free Survival. Started Apr 2018; status: active, not recruiting.
02
Drugs
ibrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03462719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03462719.